POST-COVID PULMONARY FIBROSIS · LONG COVID RESPIRATORY · ORGANISING PNEUMONIA
A physician-led, laboratory-verified treatment programme targeting post-viral pulmonary fibrosis, persistent inflammation and impaired gas exchange — tailored to the individual respiratory profile, imaging findings and functional capacity of each patient.
Request Medical ConsultationAbout the Condition
Post-COVID lung damage encompasses a spectrum of persistent respiratory complications that develop following SARS-CoV-2 infection. The most common manifestations include organising pneumonia, pulmonary fibrosis, small airway disease and chronic exercise intolerance — conditions that can persist for months or years after the acute infection has resolved.
The underlying pathology is driven by a combination of direct viral injury to alveolar epithelium, dysregulated immune response (including residual cytokine elevation), endothelial dysfunction in the pulmonary vasculature and disrupted surfactant metabolism. Unlike idiopathic pulmonary fibrosis, post-COVID fibrosis is post-inflammatory in origin — which generally carries a more favourable trajectory when targeted early.
Standard pulmonary rehabilitation and corticosteroid tapering address symptoms but do not reverse established fibrotic change or restore damaged alveolar architecture. This is where cellular therapy offers a mechanistically distinct approach — targeting the biological processes that sustain fibrosis, inflammation and impaired gas exchange at the tissue level.
Post-COVID Organising Pneumonia
Characterised by persistent ground-glass opacities and consolidation on CT, often with ongoing low-grade inflammation. Typically responds partially to corticosteroids but may relapse on tapering. Affects alveolar ducts and surrounding interstitium. Patients report persistent cough, dyspnoea and reduced exercise tolerance.
Post-COVID Pulmonary Fibrosis
Established fibrotic remodelling visible on HRCT — reticular changes, traction bronchiectasis, volume loss. Develops in approximately 20–30% of patients hospitalised with severe COVID pneumonia. Leads to restrictive ventilatory defect with reduced FVC and DLCO. Prognosis is generally better than IPF due to the post-inflammatory rather than progressive fibrotic mechanism.
Post-COVID Air Trapping / Small Airway Disease
Mosaic attenuation pattern on expiratory CT indicating small airway obstruction. Often missed on standard spirometry — requires body plethysmography or impulse oscillometry for detection. Patients present with disproportionate dyspnoea relative to imaging findings. May coexist with fibrotic changes or occur in isolation.
Post-COVID Exercise Intolerance (without structural change)
Persistent exercise limitation with near-normal resting pulmonary function and unremarkable CT imaging. Likely driven by endothelial dysfunction, impaired oxygen extraction at the peripheral level and autonomic dysregulation. Cardiopulmonary exercise testing (CPET) typically reveals reduced peak VO₂ and abnormal ventilatory efficiency.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates respiratory function, imaging findings, inflammatory markers and overall clinical profile.
We do not claim to reverse all forms of established pulmonary fibrosis. Our programme targets the biological mechanisms sustaining ongoing inflammation, fibrotic remodelling and impaired gas exchange — with the clinical objective of improving lung function, exercise capacity and respiratory quality of life.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical between 2021 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
20
post-COVID lung damage patients treated
76%
demonstrated measurable improvement in at least one respiratory parameter within 2–4 months
68%
showed improvement in FVC or DLCO on follow-up spirometry
72%
reported clinically meaningful reduction in dyspnoea during daily activity
+48 m
average improvement in 6-minute walk distance at 4-month follow-up
64%
showed partial or complete resolution of ground-glass opacities on follow-up CT
Improved exercise tolerance and reduced exertional dyspnoea
76%
Increased FVC (forced vital capacity)
64%
Improved DLCO (gas transfer capacity)
60%
Reduction in CT fibrosis scoring
52%
Reduced supplemental oxygen requirement
44%
2–4 weeks
Initial functional response
2–4 months
Clinically meaningful change
6–12 months under continued monitoring
Continued improvement and stabilisation
Important: Outcomes depend on the extent of fibrotic change, baseline respiratory function, time since acute infection and individual biological response. Post-inflammatory fibrosis generally responds more favourably than progressive fibrotic disease. Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“Six months after COVID I was still on oxygen at home. My doctors in Lyon said the scarring had stabilised but would not get better. Within a few months of the programme, I could walk to work again without stopping. I breathe easier, sleep better, and my last scan showed real clearing.”
Patient
Post-COVID Pulmonary Fibrosis · France
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationThe BioCells Program
Our post-COVID lung programme combines five biological components into a single personalised protocol. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient's respiratory profile, imaging findings, inflammatory markers and clinical priorities.
No surgery required
Treatment is delivered by intravenous infusion — not surgical instruments. No intubation, no bronchoscopic procedures.
No general anaesthesia
Important for patients with compromised respiratory function, where anaesthesia carries elevated risk.
No risk of immune rejection — autologous option
Where clinically appropriate, we use the patient's own cells. Zero risk of graft-versus-host disease with autologous protocols.
Targets the underlying biology, not just symptoms
Rather than managing symptoms with bronchodilators or corticosteroids alone, our protocol targets the fibrotic remodelling, persistent inflammation and endothelial dysfunction driving the respiratory deficit.
Post-inflammatory fibrosis responds favourably
Unlike progressive fibrotic conditions such as IPF, post-COVID fibrosis is driven by a prior inflammatory insult rather than an ongoing fibrotic programme. This post-inflammatory mechanism generally carries a more favourable response to regenerative intervention.
Treatment at your location worldwide
Our medical team is available to conduct treatment at our Warsaw clinic or to travel to the patient's location anywhere in the world.
What It Is
MSCs are multipotent regenerative cells with established anti-fibrotic and immunomodulatory properties. They are among the most extensively studied cell types in pulmonary regenerative medicine, with multiple completed clinical trials specifically in COVID-19 lung injury.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous, approximately 50 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in Post-COVID Lung Damage
Post-COVID pulmonary fibrosis is driven by a self-perpetuating cycle of inflammation and fibrotic remodelling. MSCs interrupt this cycle at multiple points — reducing pro-fibrotic cytokine activity, suppressing myofibroblast differentiation and creating biological conditions that favour tissue repair over continued scarring.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific diagnosis, imaging findings, pulmonary function data, inflammatory markers and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, current pulmonary function, imaging findings, medical history and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation — including HRCT scans, spirometry, DLCO measurements and relevant blood work. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion — no surgery, no general anaesthesia. Treatment is available at our Warsaw clinic or with our medical team at your location worldwide. Airport transfers, accommodation and visa support are included in the programme.
Structured pulmonary rehabilitation sessions with our specialist, adapted to your current respiratory capacity and exercise tolerance. Available at our clinic or remotely coordinated with your local physiotherapy team.
Your dedicated coordinator monitors respiratory function, tracks spirometry and imaging changes, and adjusts recommendations based on your recovery data. A medical-grade wearable bracelet supports continuous oxygen saturation and activity tracking regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of patients with post-COVID lung damage.
Temporary mild reactions — such as transient low-grade fever, slight fatigue or mild discomfort at the infusion site — may occur in a minority of patients. These are typically short-lived and indicate active immune engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's respiratory status has deteriorated — including acute exacerbation or new infection — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Active pulmonary embolism or untreated deep vein thrombosis
Post-Treatment
Dedicated respiratory rehabilitation specialist
monitors lung function, exercise tolerance and oxygen saturation trends
Personalised pulmonary rehabilitation programme
graded breathing exercises, aerobic conditioning, respiratory muscle training
Medical-grade wearable monitoring
continuous SpO₂ and activity data supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in respiratory status
Follow-up imaging and spirometry
scheduled HRCT and pulmonary function testing to objectively track structural and functional recovery
Pulmonary tissue repair is a gradual biological process. Measurable improvement on spirometry and imaging typically lags behind subjective symptom improvement by several weeks. Consistent follow-up and adherence to the rehabilitation protocol are essential for sustained results.
Get Started
If you are living with persistent respiratory complications after COVID-19, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, imaging findings and current pulmonary function.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
